One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their weight in 36 weeks, according to early-stage trial results on Friday, boosting the drugmaker's shares.

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo Nordisk A/S (NYSE: NVO).

Novo Nordisk today announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and amylin receptor agonist intended for once weekly

Trump has threatened to impose "very high" tariffs on Denmark if it doesn't sell Greenland ... Lilly could launch another obesity drug, weight-loss pill orforglipron, in early 2026.

Interestingly, celebrities like Elon Musk, Oprah Winfrey and Amy Schumer, among others, have also endorsed drugs like Ozempic after using them for weight loss. In India, too, the weight loss transition of celebrities like Karan Johar, Kusha Kapila, Tanmay Bhat, etc, have been linked to Ozempic, though they have denied taking these medicines.

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat substance abuse disorders, psychosis, infections, cancer and dementia, a sweeping new study shows.

Weight loss medications Ozempic and Wegovy, in particular, have been scrutinized for their high out-of-pocket costs.

The prime minister does a European tour while announcing more spending on security around the island, following President Trump’s stated desire to have Greenland, a semiautonomous Danish territory, as part of the U.

Novo Nordisk’s amycretin shows 22% weight loss over 36 weeks, potentially surpassing Eli Lilly’s Zepbound. Further trials are planned.

Denmark said on Monday it would spend 14.6 billion Danish crowns ($2.05 billion) boosting its military presence in the Arctic, following renewed interest by U.S. President Donald Trump in controlling Greenland,

Partly cloudy. Slight chance of a shower in the south this morning. Near zero chance of rain elsewhere. Winds southerly 15 to 25 km/h turning southeasterly 20 to 30 km/h in the afternoon. Daytime maximum temperatures 23 to 28. Mostly sunny. Winds east to ...

Novo Nordisk’s subcutaneous form of amycretin achieved estimated weight loss of 22% at six months in a Phase 1b/2a clinical trial, the Danish company said Friday.